Treatment strategies have not been well established for thrombotic microangiopathy associated with malignant hypertension.

Implantable cardioverter-defibrillators were no better than amiodarone for survival in chronic Chagas cardiomyopathy, though ...

Novartis, Pfizer, Otsuka and Novo Nordisk have been called out by the UK’s Prescription Medicines Code of Practice Authority (PMCPA) for breaching the Association of the British Pharmaceutical ...

AstraZeneca has bought rights to an orally-active drug that inhibits PCSK9, offering a patient-friendly alternative to current cholesterol-lowering therapies that have to be delivered via a needle.

Protocol: VAL-1221 for the treatment of patients with Lafora disease: study protocol for a single-arm, open-label clinical trial (18 October, 2024) ...